Literature DB >> 8046608

Newly discovered photodegradation products of nifedipine in hospital prescriptions.

N Hayase1, Y Itagaki, S Ogawa, S Akutsu, S Inagaki, Y Abiko.   

Abstract

New photodegradation products of nifedipine (1) have been isolated. They were found in tablets dispensed in the pulverized form by hospitals. 1 decomposed concurrently into six components after storage of 30 days under exposure to normal room light. The main photoproduct was a nitroso derivative (2) and others were minor. Preparative thin-layer chromatography has been used to isolate the six photodegradation products. The chemical structures of these isolated compounds were identified or estimated by comparison with authentic samples and/or using UV, IR, 1H NMR, mass spectroscopy, melting point determination, and elementary analysis. From these analyses, it was found that 1 was converted into a cis-azoxy derivative (4), a trans-azoxy derivative (5), a N,N'-dioxide derivative (6) and a lactam derivative (7) in addition to 2 and a nitro derivative (3). Furthermore, it is proposed that 2 is mainly responsible for the formation of these new products (4-7) by photochemical condensation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8046608     DOI: 10.1002/jps.2600830417

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  Electrochemical and spectroelectrochemical behavior of the main photodegradation product of nifedipine: the nitrosopyridine derivative.

Authors:  L J Núñez-Vergara; S Bollo; J Fuentealba; J C Sturm; J A Squella
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

2.  Development of a UV-Stabilized Topical Formulation of Nifedipine for the Treatment of Raynaud Phenomenon and Chilblains.

Authors:  Ellen K Wasan; Jinying Zhao; Joshua Poteet; Munawar A Mohammed; Jaweria Syeda; Kevin Soulsbury; Jacqueline Cawthray; Amanda Bunyamin; Chi Zhang; Brian M Fahlman; Ed S Krol
Journal:  Pharmaceutics       Date:  2019-11-09       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.